SPRY4抗体

+ +

•  

   

     Western blot analysis of Kappa light chain expression in human plasma lysate.    

  
  

The SPRY4 antibody targets the SPRY domain-containing protein 4 (SPRY4), a member of the SPRY family involved in regulating receptor tyrosine kinase (RTK) signaling pathways. SPRY4 acts as a negative modulator of the MAPK/ERK cascade, influencing cell proliferation, differentiation, and survival. Initially identified for its role in embryonic development, SPRY4 has gained attention in cancer research due to its dual context-dependent roles. Studies suggest it may act as a tumor suppressor in certain cancers (e.g., melanoma, colorectal cancer) by inhibiting oncogenic signaling, while paradoxically promoting metastasis in others (e.g., hepatocellular carcinoma) under specific microenvironmental conditions.

SPRY4 antibodies are widely used in research to detect protein expression and localization via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate SPRY4's interaction with pathways such as FGF and VEGF, offering insights into its regulatory mechanisms. Commercial SPRY4 antibodies are typically validated for specificity across human and mouse samples, with some clones cross-reacting with other species.

Research utilizing SPRY4 antibodies has implications for understanding cancer progression, drug resistance, and therapeutic targeting. Dysregulation of SPRY4 is linked to poor prognosis in multiple cancers, making it a potential biomarker or therapeutic target. However, its functional complexity necessitates careful interpretation of experimental results, emphasizing the importance of antibody validation in context-specific studies.